| Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Z Younossi, QM Anstee, M Marietti, T Hardy, L Henry, M Eslam, J George, ... Nature reviews Gastroenterology & hepatology 15 (1), 11-20, 2018 | 4550 | 2018 |
| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 2989 | 2020 |
| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 2459 | 2020 |
| Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis QM Anstee, G Targher, CP Day Nature reviews Gastroenterology & hepatology 10 (6), 330-344, 2013 | 1930 | 2013 |
| Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1526 | 2018 |
| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee Journal of hepatology 62 (5), 1148-1155, 2015 | 1199 | 2015 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1106 | 2016 |
| From NASH to HCC: current concepts and future challenges QM Anstee, HL Reeves, E Kotsiliti, O Govaere, M Heikenwalder Nature reviews Gastroenterology & hepatology 16 (7), 411-428, 2019 | 1087 | 2019 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 1081 | 2023 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1044 | 2019 |
| Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases LA Adams, QM Anstee, H Tilg, G Targher Gut 66 (6), 1138-1153, 2017 | 1026 | 2017 |
| Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research QM Anstee, RD Goldin International journal of experimental pathology 87 (1), 1-16, 2006 | 966 | 2006 |
| Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ... Gastroenterology 156 (6), 1717-1730, 2019 | 956 | 2019 |
| Cellular senescence drives age-dependent hepatic steatosis M Ogrodnik, S Miwa, T Tchkonia, D Tiniakos, CL Wilson, A Lahat, CP Day, ... Nature communications 8 (1), 15691, 2017 | 779 | 2017 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 769 | 2021 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 717 | 2020 |
| TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ... Nature communications 5 (1), 4309, 2014 | 674 | 2014 |
| Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis S McPherson, T Hardy, JF Dufour, S Petta, M Romero-Gomez, M Allison, ... Official journal of the American College of Gastroenterology| ACG 112 (5 …, 2017 | 658 | 2017 |
| Nonalcoholic fatty liver disease: pathogenesis and disease spectrum T Hardy, F Oakley, QM Anstee, CP Day Annual review of pathology: mechanisms of disease 11, 451-496, 2016 | 597 | 2016 |
| Carriage of the PNPLA3 rs738409 C> G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma YL Liu, GL Patman, JBS Leathart, AC Piguet, AD Burt, JF Dufour, CP Day, ... Journal of hepatology 61 (1), 75-81, 2014 | 562 | 2014 |
C DayNewcastle UniversityVerificeret mail på ncl.ac.uk
